BioStock: Annexin’s CSO on progress in cancer initiative

One of Annexin Pharmaceuticals’ important achievements lately is having created a conjugate of the drug candidate ANXV. By binding the candidate to a chemotherapy agent, the goal is to eventually offer a cancer treatment with a new mechanism of action where effective treatments are currently lacking. BioStock contacted the company’s CSO/CMO and co-founder Anna Frostegård to know more about the importance and the plans going forward.

Read the interview with Annexin Pharmaceuticals' CSO/CMO and co-founder Anna Frostegård here:

https://www.biostock.se/en/2023/10/annexins-cso-on-progress-in-cancer-initiative/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/